[ad_1]

As per the reports, the vaccine candidate ZyCov-D, which was developed by the Vaccine Technology Centre in Ahmedabad, showed significant immune system response in its pre-clinical trials which was done on rabbits, rats, mice and guinea pigs to test the safety and efficacy of the vaccine candidate.

To develop the potential vaccine, the company made use of two different approaches–the first was using the viral protein of the coronavirus to trigger an immune response in the body and another one was to use live attenuated recombinant measles virus to produce a vaccine for COVID-19. They eventually finalised the plasmid DNA vaccine candidate.

[ad_2]

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here